Drug
Ganirelix clinical trials
Also written Orgalutran and Org 37462.
- studies test it
- 20
- open now
- 1
- in phase 3
- 3
- first study started
- 2003
Keep track of what changes. Save the ganirelix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2020 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 3
- Phase 4
- 6
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 17
Organon and Co (2) · Yale University (2) · Yazd Research & Clinical Center for Infertility (2) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Peter y. Liu (1) · University Hospital, Lille (1) · LG Life Sciences (1) · University of Utah (1)
Often tested with
Tested in the same studies.
Follitropin beta (3) · Dexamethasone (2) · Cosyntropin (2) · Hydrocortisone (2) · Ketoconazole (1) · Lutropin alfa (1) · Estradiol (1) · Progesterone (1)
Studies
Open first, then newest update. How each study uses ganirelix is read from its arms, and is right about nine times in ten.
Testing it · 20
- Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife WomenRecruitingPhase 4University of DelawareNCT06745466Written as ganirelix acetate
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenActive, not recruitingEarly Phase 1Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT04037605Written as Ganirelix
- Hormonal Mechanisms of Sleep Restriction - Axis StudyActive, not recruitingPhase 1Peter y. LiuNCT03142893Written as Ganirelix
- Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.CompletedEarly Phase 1University Hospital, LilleNCT05751252Written as Ganirelix
- Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)CompletedPhase 2Organon and CoNCT00988260Written as Ganirelix
- A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)CompletedPhase 3Organon and CoNCT00725491Written as ganirelix
- Delayed Start to Ovarian StimulationTerminatedPhase 4University of California, San FranciscoNCT01614067Written as Ganirelix acetate
- To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®CompletedPhase 4LG Life SciencesNCT03051087Written as Ganirelix acetate
- Sex Hormones and Orthostatic ToleranceCompletedPhase 2Yale UniversityNCT01153581Written as Ganirelix acetate
- Cetrorelix and Ganirelix Flexible Protocol for (IVF)Status unknownPhase 4Università degli Studi 'G. d'Annunzio' Chieti e PescaraNCT03477929Written as Ganirelix Acetate
- Follicle-Stimulating Hormone (FSH) and the Onset of PubertyCompletedEarly Phase 1University of UtahNCT00734279Written as Ganirelix - Early Puberty Ganirelix Visit
- Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.CompletedPhase 3Instituto de Investigacion Sanitaria La FeNCT02118051Written as Ganirelix 0.25 mg.
- Compromised Microcirculation in Women With Polycystic Ovary SyndromeCompletedEarly Phase 1Yale UniversityNCT00757185Written as ganirelix acetate
- Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist ProtocolStatus unknownNot applicableChong Qing Reproducive and Genetic InstituteNCT02635607Written as Ganirelix
- Luteal Phase FSH in the IVF Poor ResponderCompletedPhase 4University of PennsylvaniaNCT00225433Written as ganirelix acetate
- Antagonist/Letrozole in Poor RespondersCompletedPhase 1/2Yazd Research & Clinical Center for InfertilityNCT00823004Written as ganirelix acetate
- Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) CyclesCompletedNot applicableHouston Fertility InstituteNCT01286051Written as Follistim plus Ganirelix
- A Novel Approach to Endometrial Preparation in Recipients of Donor EggsStatus unknownNot applicableKelly, Maureen, M.D.NCT01424618Written as Ganirelix
- Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRHStatus unknownPhase 3Yazd Research & Clinical Center for InfertilityNCT00823602Written as ganirelix
- Early Follicular Supplementation of Ganirelix in IVF 2004CompletedPhase 4The Baruch Padeh Medical Center, PoriyaNCT00461422Written as Ganirelix
Given in every arm · 11 — ganirelix is usual care beside what is tested
- Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained InfertilityRecruitingNot applicableAndros Day Surgery ClinicNCT06481696Written as Ganirelix Acetate 0.5 MG/ML [Fyremadel]
- To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as ReferenceCompletedPhase 3Changchun GeneScience Pharmaceutical Co., Ltd.NCT06091436Written as Ganirelix
- Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)CompletedPhase 2Organon and CoNCT00702806Written as Orgalutran®
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)CompletedPhase 3Organon and CoNCT00696800Written as Ganirelix
- An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)WithdrawnPhase 3Organon and CoNCT01599494Written as Ganirelix
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response PatientCompletedNot applicableReproductive & Genetic Hospital of CITIC-XiangyaNCT03300518Written as Ganirelix
- Sex Hormones and Atherosclerosis Prevention in Perimenopausal WomenCompletedNot applicableUniversity of Colorado, DenverNCT00608062Written as GnRHant - Ganirelix acetate
- Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank DonationCompletedPhase 4Michigan Reproductive MedicineNCT02069808Written as Ganirelix
- Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders TrialCompletedPhase 3Universitair Ziekenhuis BrusselNCT01816321Written as Ganirelix
- Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian StimulationCompletedNot applicableFundacion DexeusNCT01645241Written as ganirelix
- MENOPUR® Versus FOLLISTIM®CompletedPhase 4Ferring PharmaceuticalsNCT00802360Written as Ganirelix
As the comparator · 9 — what is tested is compared with ganirelix
- Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)Not yet recruitingNot applicableCentro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)NCT07732348Written as Ganirelix ; Cetrorelix
- PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over StudyRecruitingPhase 4University Hospital, GhentNCT06175832Written as Orgalutran®
- Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.Not yet recruitingPhase 4GinefivNCT06637189Written as Ganirelix
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.CompletedPhase 4Instituto BernabeuNCT05954962Written as Ganirelix Acetate
- Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian StimulationCompletedPhase 3Instituto Valenciano de Infertilidad, IVI VALENCIANCT03300960Written as Ganirelix (GnRH antagonist)
- Desogestrel Versus GnRH Antagonist in IVF/ICSIStatus unknownPhase 4Casa di Cura Privata Villa MafaldaNCT04728659Written as Orgalutran
- The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation CyclesStatus unknownPhase 4Casa di Cura Privata Villa MafaldaNCT04654741Written as Ganirelix Acetate
- Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte DonorsCompletedPhase 4Fundació Privada EuginNCT02796105Written as Orgalutran
- A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian StimulationCompletedPhase 4EMD SeronoNCT00298025Written as Antagon ™
Codes
What other systems call ganirelix · ClinicalTrials.gg INT003459
- MeSH (NLM) C061018ganirelixConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) IX503L9WN0GANIRELIXConfirmed FDA, NLM, Wikidata
- RxNorm 35825Confirmed FDA, Wikidata
- Wikidata Q5521314GanirelixConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77423GanirelixConfirmed FDA, Wikidata
- DrugBank DB06785One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C061018 | ganirelix | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | IX503L9WN0 | GANIRELIX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 35825 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5521314 | Ganirelix | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77423 | Ganirelix | Confirmed FDA, Wikidata |
| DrugBank | DB06785 | — | One source Wikidata |
Also registered as ganirelix acetate (UNII 56U7906FQW · RxNorm 259264).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.